BioSpace News Archive

Genetown

CELLINK launches new bioinks to further strengthen the company’s bioink portfolio

CELLINK launches the next part of a multiphase bioink expansion. This phase includes the release of two new bioink series, the expansion of three existing bioink series, the release of a new thickener series and two products for enhanced cell analysis.

November 24, 2019
·
4 min read
New target for Parkinson’s disease therapy? Blockade of specific calcium channels can protect nerve cells

Progressive degeneration of dopamine-producing nerve cells in the brain leads to dopamine deficiency and ultimately to Parkinson’s disease.

November 24, 2019
·
4 min read
Record attendance of 4,400 life sciences executives at BIO-Europe® 2019 25th annual celebration in Hamburg

The highly anticipated 25th annual BIO-Europe® international life sciences partnering conference wrapped up in Hamburg, Germany, last week with an all-time high 4,400 attendees from 2,300 companies and 61 countries, engaging in 27,375 one-to-one partnering meetings, a five percent increase over 2018.

November 24, 2019
·
3 min read
Drug Development

DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting

DNX-2401 and Pembrolizumab Combination Shows Clinical Benefit in Recurrent Glioblastoma

November 24, 2019
·
3 min read
Job Trends

HealthMine Report Published on Five Gaps Between Medicare Advantage Plans and Beneficiaries Hindering a Personalized Experience

HealthMine, the health action engagement company, published a report as part of its series on Medicare Advantage Plan Beneficiary Insights, entitled: “Closing Gaps to Create a Personalized Experience.” The report covers five gaps between Medicare beneficiaries and their health plans.

November 24, 2019
·
2 min read
Deals

The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion

The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price

November 24, 2019
·
10 min read
Biotech Beach

AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa

Preclinical research will pair AVITA Medical’s Spray-On Skin™ Cells technology and expertise with the Gates Center’s patent-pending combined reprogramming and gene-editing methodology

November 24, 2019
·
8 min read